OVCA429细胞系

OVCA429细胞OVCA429细胞系OVCA429人卵巢癌细胞

Cell line name OVCA429

Synonyms OVCA 429; OvCA 429; OVCA-429; OVCAR-429; OVCAR 429; OVCAR429; OV429

Accession CVCL_3936

Resource Identification Initiative To cite this cell line use: OVCA429 (RRID:CVCL_3936)

Comments Part of: MD Anderson Cell Lines Project.

Doubling time: 34.58 hours (JWGray panel).

Omics: Array-based CGH.

Omics: Genome sequenced.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: In situ; Ovary; UBERON=UBERON_0000992.

Sequence variations

Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro151His (c.452C>A); ClinVar=VCV000376639; Zygosity=Unspecified (PubMed=20204287).

HLA typing Source: PubMed=26589293

Class I

HLA-A A*26:01,26:01

HLA-B B*39:01,39:01

HLA-C C*12:03,12:03

Disease Ovarian cystadenocarcinoma (NCIt: C5228)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy Children:

CVCL_JY92 (OVCA429/GFP) CVCL_CZ99 (OVCA429/T40) CVCL_CZ98 (OVCA429/TxT50)

Sex of cell Female

Age at sampling Age unspecified

Category Cancer cell line

STR profile Source(s): PubMed=20596667; PubMed=22710073; PubMed=25877200; PubMed=30485824

 

Markers:

Amelogenin X

CSF1PO 12,13 (PubMed=20596667; PubMed=22710073; PubMed=25877200)

12,13,14 (PubMed=30485824)

D2S1338 19,20

D3S1358 15,16

D5S818 11,12

D7S820 11,12

D8S1179 14,15

D13S317 7,12 (PubMed=22710073; PubMed=25877200; PubMed=30485824)

12 (PubMed=20596667)

D16S539 12

D18S51 14

D19S433 13

D21S11 30

FGA 24

Penta D 13,14

Penta E 12

TH01 9

TPOX 9,11

vWA 16,18

 

Run an STR similarity search on this cell line

Publications

PubMed=7028788; DOI=10.1172/JCI110380; PMCID=PMC370929

Bast R.C. Jr., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., Knapp R.C.

Reactivity of a monoclonal antibody with human ovarian carcinoma.

J. Clin. Invest. 68:1331-1337(1981)

 

PubMed=6346879; DOI=10.1016/0002-9378(83)90999-7

Berkowitz R.S., Kabawat S., Lazarus H., Colvin R.B., Knapp R.C., Bast R.C. Jr.

Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human epithelial ovarian carcinoma cell line.

Am. J. Obstet. Gynecol. 146:607-612(1983)

 

PubMed=1536252; DOI=10.1016/0002-9378(92)91697-9

Berchuck A., Rodriguez G., Olt G., Whitaker R., Boente M.P., Arrick B.A., Clarke-Pearson D.L., Bast R.C. Jr.

Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta.

Am. J. Obstet. Gynecol. 166:676-684(1992)

 

PubMed=10318951; DOI=10.1073/pnas.96.10.5722; PMCID=PMC21927

Lau K.-M., Mok S.C., Ho S.-M.

Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells.

Proc. Natl. Acad. Sci. U.S.A. 96:5722-5727(1999)

 

PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H

Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.

Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.

Mol. Carcinog. 28:236-246(2000)

 

PubMed=12080474; DOI=10.1038/sj.onc.1205542

Manzano R.G., Montuenga L.M., Dayton M.A., Dent P., Kinoshita I., Vicent S., Gardner G.J., Nguyen P., Choi Y.-H., Trepel J.B., Auersperg N., Birrer M.J.

CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential.

Oncogene 21:4435-4447(2002)

 

PubMed=12960427; DOI=10.1091/mbc.E03-05-0279; PMCID=PMC266758

Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O.G., Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H., Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J., Kristensen G.B., Borresen-Dale A.-L., Hastie T.J., Tibshirani R., van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O., Sikic B.I.

Gene expression patterns in ovarian carcinomas.

Mol. Biol. Cell 14:4376-4386(2003)

 

PubMed=16380993; DOI=10.1002/ijc.21671

Huang K.-C., Park D.C., Ng S.-K., Lee J.Y., Ni X.-Y., Ng W.-C., Bandera C.A., Welch W.R., Berkowitz R.S., Mok S.C., Ng S.-W.

Selenium binding protein 1 in ovarian cancer.

Int. J. Cancer 118:2433-2440(2006)

 

PubMed=16382445; DOI=10.1002/gcc.20300

Wang Y.C., Juric D., Francisco B., Yu R.X., Duran G.E., Chen G.K., Chen X., Sikic B.I.

Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines.

Genes Chromosomes Cancer 45:365-374(2006)

 

PubMed=19926575; DOI=10.1309/AJCPTK87EMMIKPFS; PMCID=PMC3040237

DeRycke M.S., Andersen J.D., Harrington K.M., Pambuccian S.E., Kalloger S.E., Boylan K.L.M., Argenta P.A., Skubitz A.P.N.

S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival.

Am. J. Clin. Pathol. 132:846-856(2009)